Company profile
AMARIN CORP PLC\UK
NASDAQ:AMRNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AMEN | approved | — | 5 | approved |
| VASCEPA | approved | — | 3 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01492361 | phase3 | completed | 2011-11-01 | 2018-05-01 | Amarin Pharma Inc. | A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin |
| NCT01047501 | phase3 | completed | 2009-12-01 | 2011-02-01 | Amarin Pharma Inc. | Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) |
| NCT01047683 | phase3 | completed | 2009-12-01 | 2010-10-01 | Amarin Pharma Inc. | Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL |
| NCT00146211 | phase3 | completed | 2005-09-01 | 2007-08-01 | Amarin Neuroscience Ltd | TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 202057 | 2012-07-26 | NDA | AMARIN PHARMACEUTICALS IRELAND LTD | |||||
Loading… | ||||||||
| ANDA 083242 | — | ANDA | AMARIN PHARMACEUTICALS INC | |||||
Loading… | ||||||||